Sustanon 250

Phase 1Small molecule

UUniversity of Nottingham

Sustanon 250 is one of 6 small molecule programs targeting Quality of Life. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Quality of LifeRecruiting

Quality of LifePhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Quality of Life

#DrugCompanyPhaseTrials

Tryptyr

FFalcon

Approved

1 2

Pilocarpine Hcl

AbbVie

Phase 3

1 3

R-Gene 10

PPharmacia and Upjohn

Preclinical

1 4

Opioids

SSahlgrenska University Hospital

Preclinical

1 5

Sustanon 250

UUniversity of Nottingham

Phase 1

1 6

Medications

YYale University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Quality of Life

NCT07143279

Clinical

Trials by Indication[1]

Systemic1 trial

Systemic Hormones and Muscle Protein Synthesis

Unknown status·UUniversity of Nottingham·Phase 3·NCT03054168·34 enrolled

Quality of Life1 trial

Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life

Recruiting·JJules Bordet Institute·Phase 1·NCT07143279·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sustanon 250. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sustanon 250 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sustanon 250. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Nottingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Nottingham

Sustanon 250

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Systemic1 trial

Quality of Life1 trial

References

Drug Info

Quick Facts

Related News